Table Of Contents
1 Introduction 18
1.1 Overview Of Asia-Pacific Advanced Wound Care Market 18
1.2 Currency And Pricing 20
1.3 Limitation 20
1.4 Markets Covered 21
2 Market Segmentation 24
2.1 Markets Covered 24
2.2 Geographic Scope 25
2.3 Years Considered For The Study 26
2.4 Currency And Pricing 26
2.5 Research Methodology 27
2.6 Primary Interviews With Key Opinion Leaders 30
2.7 Secondary Sources 31
2.8 Assumptions 31
3 Market Overview 32
3.1 Drivers 34
3.1.1 Rising Ageing And Geriatric Population 34
3.1.2 Technological Advancement 34
3.1.3 Government Support 35
3.1.4 Rising Incidences Of Chronic Wound 36
3.1.5 Increasing Trend 37
3.2 Restraints 37
3.2.1 Low Awareness 37
3.2.2 Slow Growth Rate And Shrinking Market 38
3.2.3 Complex Regulatory Approval Process 38
3.2.4 Competition With Other Moist Dressings 39
3.3 Opportunities 39
3.3.1 Reimbursement 39
3.3.2 Mergers And Acquisitions To Expand Business 40
3.3.3 Unmet Needs 40
3.3.4 Increasing Demand 41
3.4 Challenges 41
3.4.1 Shortage Of Trained Staff 41
3.4.2 The Development Of Substitute Products 41
3.5 Key Market Trends And Upcomming Technologies 42
3.5.1 Smart Dressing Will Push Future Growth 42
3.5.2 Hydrofiber Has Been The Most Significant Recent Innovation 42
3.5.3 Alginate Dressing Is Expected To Grow Robustly In The Upcoming Years 42
3.5.4 Foam Dressing Accounting The Largest Market Segment In The Upcoming Years 42
4 Executive Summary 43
5 Premium Insights 46
6 Asia-Pacific Advanced Wound Care Market, By Product Type 49
6.1 Overview 50
6.2 Dressing 52
6.2.1 Dressing On The Basis Of Product Type 53
6.2.1.1 Film Dressings 53
6.2.1.2 Foam Dressings 54
6.2.1.3 Hydrogels 54
6.2.1.4 Alginates 55
6.2.1.5 Wound Contact Layer 55
6.2.1.6 Super Absorbent Dressing 56
6.3 Biologics 57
6.3.1 Biologics On The Basis Of Product Type 57
6.3.1.1 Allografts 58
6.3.1.2 Synthetic Skin Grafts 58
6.3.1.3 Xenografts 58
6.3.1.4 Growth Factors 59
6.3.1.4.1 Platelet Derived Growth Factor (Pdgf) 59
6.3.1.4.2 Platelet Rich Plasma (Prp) 59
6.3.1.4.3 Epidermal Growth Factors (Egf) 61
6.3.1.4.4 Basic Fibroblast Growth Factors (Bfgf) 61
6.3.1.4.5 Granulocyte Colony Stimulating Factor (G-Csf) 61
6.3.1.4.6 Talactoferrin Alfa 62
6.3.1.4.7 Thrombin Peptide 62
6.3.1.4.8 Keratinocy Growth Factor (Kgf) 62
6.4 Therapy Devices 63
6.4.1 Therapy Devices On The Basis Of Product Type 63
6.4.1.1 Negative Pressure Wound Therapy (Npwt) 64
6.4.1.1.1 Portable Npwt Devices 64
6.4.1.1.2 Disposable Npwt Devices 65
6.4.1.2 Pressure Relief Devices 65
6.4.1.3 Hyperbaric Oxygen Chambers 65
6.4.1.3.1 Monoplace 65
6.4.1.3.2 Multiplace 66
6.4.1.3.3 Topical 66
6.4.1.4 Wound Debridement Devices 67
6.4.1.4.1 Hydrosurgical 67
6.4.1.4.2 Ultrasound 67
6.4.1.4.3 Mechanical 67
6.4.1.4.4 Others 67
6.4.1.5 Physical Therapies 68
6.4.1.5.1 Laser Therapy 68
6.4.1.5.2 Electrical Stimulation 68
6.4.1.5.3 External Shock Wave Therapies 69
6.4.1.5.4 Saline Mist Therapy 69
7 Asia-Pacific Advanced Wound Care Market, By Wound Type 70
70
7.1 Introduction 71
7.2 Surgical Wound 73
7.2.1 Class I 73
7.2.2 Class Ii 73
7.2.3 Class Iii 73
7.2.4 Class Iv 73
7.3 Diabetic Ulcers 74
7.4 Pressure Ulcers 75
7.5 Venous Ulcers 76
7.6 Burns 76
8 Asia-Pacific Advanced Wound Care Market, By End User 77
8.1 Overview 78
8.2 Hospitals 79
8.3 Wound Care Centers 79
8.4 Ambulatory Centers 79
8.5 Home Healthcare 79
8.6 Clinics 80
8.7 Community Healthcare 80
9 Asia-Pacific Advanced Wound Care Market, By Distribution Channel 81
9.1 Overview 82
9.2 Direct Tenders 82
9.3 Retail 82
10 Asia-Pacific Advanced Wound Care Market By Geography 83
10.1 Asia-Pacific 83
10.1.1 Japan 96
10.1.2 China 103
10.1.3 South Korea 110
10.1.4 India 117
10.1.5 Australia 124
10.1.6 Thailand 130
10.1.7 Singapore 137
10.1.8 Malaysia 144
10.1.9 Philippines Advanced Wound Care Market 151
10.1.10 Indonesia 158
10.1.11 Rest Of Asia-Pacific 165
11 Asia-Pacific Advanced Wound Care Market, Company Share 166
11.1 Company Share Analysis; Asia-Pacific (Apac) 166
12 Company Profile 167
12.1 Acelity L.P. Inc. (Subsidary Of Allargan) 167
12.1.1 Company Overview 167
12.1.2 Company Share Analysis 167
12.1.3 Product Portfolio 168
12.1.4 Recent Developments 170
12.2 Smith And Nephew 171
12.2.1 Company Overview 171
12.2.2 Company Share Analysis 171
12.2.3 Revenue Analysis 172
12.2.4 Product Portfolio 172
12.2.5 Recent Developments 173
12.3 Molnlycke Healthcare 174
12.3.1 Company Overview 174
12.3.2 Company Share Analysis 174
12.3.3 Asia-Pacific Presence 175
12.3.4 Product Portfolio 175
12.3.5 Recent Developments 176
12.4 3M 177
12.4.1 Company Overview 177
12.4.2 Company Share Analysis 177
12.4.3 Revenue Analysis 178
12.4.4 Product Portfolio 178
12.4.5 Recent Developments 180
12.5 Baxter 181
12.5.1 Company Overview 181
12.5.2 Revenue Analysis 181
12.5.3 Product Portfolio 182
12.5.4 Recent Developments 182
12.6 Coloplast 183
12.6.1 Company Overview 183
12.6.2 Revenue Analysis 183
12.6.3 Product Portfolio 184
12.6.4 Recent Developments 184
12.7 Convatec Inc. 185
12.7.1 Company Overview 185
12.7.2 Revenue Analysis 185
12.7.3 Product Portfolio 186
12.7.4 Recent Developments 187
12.8 Derma Sciences Inc (Subsidiary Of Integra Life Sciences) 188
12.8.1 Company Overview 188
12.8.2 Asia-Pacific Presence 188
12.8.3 Product Portfolio 188
12.8.4 Recent Developments 190
12.9 Ethicon Inc (Subsidiary Of Johnson And Johnson Services, Inc ) 191
12.9.1 Company Overview 191
12.9.2 Asia-Pacific Presence 191
12.9.3 Product Portfolio 192
12.9.4 Recent Developments 192
12.10 Integra Life Sciences Corporation 193
12.10.1 Company Overview 193
12.10.2 Revenue Analysis 193
12.10.3 Product Portfolio 194
12.10.4 Recent Developments 195
12.11 Paul Hartmann Limited 196
12.11.1 Company Overview 196
12.11.2 Revenue Analysis 196
12.11.3 Product Portfolio 197
12.11.4 Recent Development 197
12.12 Organogenesis Inc 198
12.12.1 Company Overview 198
12.12.2 Asia-Pacific Presence 198
12.12.3 Product Portfolio 199
12.12.4 Recent Developments 199
13 Related Reports 200
?